Nevada committee considers bill letting providers request clinic name on abortion‑medication labels; debate centers on safety vs. provider privacy

Assembly Member Sandra Howtegui presented Assembly Bill 411 to allow, upon a prescribing provider’s request, the label on dispensed prescriptions for mifepristone and misoprostol to show the health‑care practice name instead of the individual prescriber’s name. The sponsor framed the bill as a privacy and safety measure for reproductive‑health providers who face targeted harassment and, in some states, criminal liability for prescribing medication abortion.

Howtegui said the bill does not change who may prescribe or the legality of medication abortion in Nevada; it amends label practice only, and she indicated she is working on an amendment to extend criminal‑penalty protections to pharmacists consistent with protections already provided to physicians in Nevada law.

Supporters including Planned Parenthood Advocates and Reproductive Freedom for All Nevada said the change would reduce threats and encourage providers and pharmacists to continue offering medication abortion care. “AB 411 is a simple bill that will protect health care providers from harassment while preserving safe, legal access to care for patients across Nevada,” a Planned Parenthood organizer told the committee.

Opponents included nurses, pregnancy resource centers, Nevada Right to Life, and several individual clinicians and emergency‑care workers who testified that removing the prescriber’s name from the bottle could hinder emergency or follow‑up care and reduce transparency and accountability. Witnesses described personal or clinical experiences in which knowing the prescribing clinician mattered for timely care. A nurse‑practitioner told the committee a patient had received a prescription by email, had no direct follow‑up, and later needed care; other testifiers recounted anecdotal adverse outcomes and urged the committee to preserve prescriber information on dispensed labels.

Legal counsel Jeff Kuleme addressed federal regulatory questions: he said federal Food and Drug Administration container‑labeling regulations (21 CFR 201.56) do not appear to require the prescribing practitioner’s name on the container label and that the drugs at issue are not controlled substances subject to DEA controlled‑substance labeling rules. Counsel’s reading indicated the bill’s label change is consistent with federal labeling rules for non‑controlled prescription drugs. Sponsor Howtegui told the committee she was negotiating an amendment to protect pharmacists from criminal liability where they comply with the label request.

Committee members asked whether pharmacies would still have the prescriber’s contact information. Counsel and the sponsor clarified that the underlying prescription record and the prescription itself would still contain the prescriber’s identity and contact information; the bill would only change the text printed on the container label furnished to the patient. Several senators raised concerns about emergency access and whether clinic contact information would be sufficient in urgent situations.

The committee heard roughly equal volumes of testimony for and against AB 411 but did not take a vote at the hearing. The sponsor said she will continue working with stakeholders on amendments to clarify pharmacist protections and to ensure patient safety while addressing provider harassment.